Dr. Stark is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2959 Sharpsburg McCullum Rd
Newnan, GA 30265Phone+1 770-502-2000Fax+1 770-502-2049
Education & Training
Emory University School of MedicineFellowship, Rheumatology, 2006 - 2008- Emory University School of MedicineResidency, Internal Medicine, 2003 - 2006
Vanderbilt University School of MedicineClass of 2003
Certifications & Licensure
GA State Medical License 2006 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACR) American College of Rheumatology
Publications & Presentations
PubMed
- 23 citationsOne-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S....Leslie R. Harrold, Heather J. Litman, Katherine C. Saunders, Kimberly J. Dandreo, Bernice Gershenson
Arthritis Research & Therapy. 2018-01-02 - 11 citationsBarriers to treatment optimization and achievement of patients' goals: perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry.K. Gavigan, W. Benjamin Nowell, Mylene S. Serna, Jeffrey L Stark, Mohamed Yassine
Arthritis Research & Therapy. 2020-01-07 - 5 citationsPGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab PegolJessica A. Walsh, Terri Arledge, T. Nurminen, Luke Peterson, Jeffrey Stark
The Journal of Rheumatology. 2018-05-01
Press Mentions
Non-Radiographic Axial Spondyloarthritis Recognized with ICD-10 CodeAugust 21st, 2020- UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque PsoriasisNovember 16th, 2023
- Immunotherapy Now Available for Treating Moderate-to-Severe Plaque PsoriasisNovember 16th, 2023
Professional Memberships
- Fellow
Industry Relationships
- Head of Medical Affairs, Rheumatology, UCB, Inc.2014 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
